Nemoto Science Co.,Ltd. is a CRO specializing in contract pharmacokinetic (PK) studies and compound synthesis.This page provides an overview of the company’s non-clinical capabilities, representative study models, and case studies.
We have summarized information below for a reference.
Nemoto Science Co.,Ltd. offers a GLP-compliant broad spectrum of studies that span from drug discovery through preclinical development.
The company handles numerous animal species—from small animals(mice and rats) to medium and large species(rabbits and non-human primates) —and offers both in vivo and in vitro studies.
Nemoto Science Co.,Ltd. performs detailed analyses using RI tracer studies with a wide range of radioisotopes (14C, 3H, 125I, 32P, 51Cr, etc.) and advanced analytical instruments including LC-MS/MS.
The company has introduced state-of-the-art technologies such as Orbitrap-based analysis of RI-dosed samples and metabolite identification via HPLC on-line LSC.
Specialized technical capabilities
Since the first GLP compliance inspection in 1998, Nemoto Science Co.,Ltd. has received an “A” or “Compliant” rating in every subsequent inspection. All of their studies are conducted at GLP-compliant facilities, enabling the company to generate high-quality and reliable non-clinical data for regulatory submission.
Mediford offers a comprehensive range of services, such as regulatory safety studies, pharmacology studies, pharmacokinetic studies, and supports exploratory research during the early stages of R&D.
Their facilities are not compliant with pharmaceutical GLP, medical device GLP, regenerative medicine GLP, agricultural chemical GLP, or the Chemical Substances Control Law GLP.
Nemoto Science Co.,Ltd. is partnered with Mediford for specialty non-clinical pharmacokinetic studies.
Nemoto Science Co.,Ltd. offers development-appropriate in vivo PK studies at GLP-compliant facilities.
They are capable of handling small animals (mice, rats, guinea pigs) as well as rabbits, dogs, and non-human primates.
Capabilities include RI tracer studies using various isotopes (14C, 3H, 125I, 32P, 51Cr) and analytical studies with LC-MS/MS and related platforms.
Study protocols and final reports can be prepared in both English and Japanese upon request.
With decades of expertise in animal experimentation, Nemoto Science Co.,Ltd. provides reproducible and reliable data for absorption, distribution, and excretion studies.
Absorption studies include measurements such as blood and plasma concentration profiles, identification of gastrointestinal absorption sites, and evaluation of portal vein absorption.
For distribution studies, they can provide tissue distribution assessments, micro-autoradiography, placental transfer studies, and plasma protein binding evaluations.
In Excretion studies, urinary, fecal, biliary, and exhaled elimination can be evaluated.
Nemoto Science Co.,Ltd. has performed studies for many pharmaceutical companies for pharmacokinetic studies using tritium-labeled compounds, as well as contract synthesis and testing throughout the discovery and development phases.
| Address | 4-10-9 Takaido Higashi, Suginami-ku, Tokyo |
|---|---|
| Tel | 03-3333-2711 |
| Website | https://www.nemotoscience.co.jp/ |
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.